Skip to main content
CRISPR Therapeutics AG logo

CRISPR Therapeutics AG — Investor Relations & Filings

Ticker · CRSP ISIN · CH0334081137 LEI · 506700O6IRRIQLT3W370 US Manufacturing
Open in API
Filings indexed 823 across all filing types
Latest filing 2017-08-02 Director's Dealing
Country CH Switzerland
Listing US CRSP

About CRISPR Therapeutics AG

https://crisprtx.com/

CRISPR Therapeutics AG is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The company leverages this technology to make precise, directed changes to genomic DNA. As a pioneer in the field, CRISPR Therapeutics has established a diverse portfolio of therapeutic programs across several disease areas, including hemoglobinopathies (such as sickle cell disease and beta-thalassemia), immuno-oncology, regenerative medicine, and cardiovascular disease. The company was one of the first to advance a CRISPR-based therapy into clinical trials and receive regulatory approval, aiming to create potentially curative treatments for patients.

Recent filings

Filing Released Lang Actions
FORM 3 SUBMISSION
Director's Dealing
2017-08-02 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The content specifically announces the hiring and appointment of a new executive, Tony W. Ho, as Executive Vice President, Head of Research and Development. There are no financial statements or detailed financial data included. The document is primarily an announcement of a management change. According to the filing definitions, announcements of changes in senior management fall under Board/Management Information (MANG). The document length is 3483 characters, which is short and consistent with an announcement rather than a full report. Therefore, the correct classification is MANG with high confidence.
2017-08-01 English
OWNERSHIP DOCUMENT
Director's Dealing
2017-07-31 English
OWNERSHIP DOCUMENT
Director's Dealing
2017-07-27 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated July 27, 2017, by CRISPR Therapeutics AG. The content focuses on the departure of a senior officer (Marc Becker, CFO) and the appointment of acting officers, as well as the search for a new CFO. There is no financial data, earnings information, or report publication mentioned. The primary subject is changes in senior management and board-related personnel updates. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under 'Board/Management Information' (MANG). The document length is 3653 characters, which is consistent with a typical 8-K announcement of management changes. Therefore, the correct classification is MANG with high confidence.
2017-07-27 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes a press release about an appellate brief related to a patent dispute, attached as Exhibit 99.1. There are no financial statements or detailed financial data presented. The document length is 3025 characters, which is relatively short and primarily serves as an announcement of an event rather than a detailed report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2017-07-25 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.